Cover Image
市場調查報告書

腎上腺腦白質失養症:開發中產品分析

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361622
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺腦白質失養症:開發中產品分析 Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 48 Pages
簡介

本報告提供腎上腺腦白質失養症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腎上腺腦白質失養症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腎上腺腦白質失養症:企業開發中的治療藥

腎上腺腦白質失養症:大學/機關研究中的治療藥

腎上腺腦白質失養症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腎上腺腦白質失養症:企業開發中的產品

腎上腺腦白質失養症:大學/機關研究中的產品

腎上腺腦白質失養症的治療藥開發企業

  • Applied Genetic Technologies Corporation
  • bluebird bio, Inc.
  • Minoryx Therapeutics s.l.
  • ReceptoPharm, Inc.
  • Viking Therapeutics, Inc.

腎上腺腦白質失養症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腎上腺腦白質失養症:最近的開發平台趨勢

腎上腺腦白質失養症:暫停中的計劃

腎上腺腦白質失養症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8118IDB

Summary

Global Markets Direct's, 'Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2016', provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
  • The report reviews pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics and enlists all their major and minor projects
  • The report assesses Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Overview
  • Therapeutics Development
    • Pipeline Products for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview
    • Pipeline Products for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Comparative Analysis
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics under Development by Companies
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics under Investigation by Universities/Institutes
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Products under Development by Companies
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Products under Investigation by Universities/Institutes
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development
    • Applied Genetic Technologies Corporation
    • bluebird bio, Inc.
    • Minoryx Therapeutics s.l.
    • ReceptoPharm, Inc.
    • Viking Therapeutics, Inc.
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DRX-065 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lenti-D - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIN-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pioglitazone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RPI-78M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Arylsulfatase A and ABCD1 for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VK-0214 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VK-2809 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Recent Pipeline Updates
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 03, 2014: Minoryx receives Orphan Drug Designation for MIN-101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2016
  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Applied Genetic Technologies Corporation, H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by bluebird bio, Inc., H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Minoryx Therapeutics s.l., H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by ReceptoPharm, Inc., H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Viking Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics - Recent Pipeline Updates, H1 2016
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2016
  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top